Biogen Ma Inc.

Biogen Idec Ma Inc.

Sunesis Pharmaceuticals, Inc.

Millennium Pharmaceuticals Limited

Millenium Pharmaceuticals, Inc.

Boigen Ma Inc.

Jermaine Thomas

Gnanasambandam Kumaravel

Kevin Guckian

Edward Yin-Shiang Lin

Guo Zhu Zheng

Richard Dana Caldwell

Bin Ma

Arthur G Taveras

Xiaogao Liu

Daniel M Scott

Wen-Cherng Lee

Zhan Shi

Sha Mi

Timothy Raymond Chan

Joseph P Lyssikatos

Brian Stuart Lucas

Tracy J Jenkins

Robert Meissner

Irina Leaf

Jeremy Duffield

Deping Wang

Lei Zhang

Lihong Sun

Daniel A Erlanson

Joseph Arndt

Jeffery Vessels

Kurt D Van Vloten

Jeffrey Vessels

Nathan Genung

Ma Bin

Daniel Erlanson

Edward Lin

Kurt Van Vloten

Kevin M Guckian

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease. 

IRAK4 inhibiting agents

The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P) receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

S1P modulating agents

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

SIP modulating agents

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Bicyclic aryl sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Heterobicyclic sphingosine 1-phosphate analogs

The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

Heterocyclic compounds useful as PDK1 inhibitors

Compounds of formula (I) or (II) can modulate the activity of SIP receptors.

Growing community of inventors

Chelsea, MA, United States of America

Jermaine Thomas